Windtree Therapeutics (NASDAQ:WINT) Files An 8-K Results of Operations and Financial Condition

Item 2.02.

On March 31, 2017, Windtree Therapeutics, Inc. (the Company)
issued a press release highlighting the results of operations for
the quarter ended December 31, 2016, and providing key financial
and business updates. The press release is attached as Exhibit
99.1 hereto.

In accordance with General Instruction B.2 of Form 8-K, the
information in Item 2.02 of this Current Report on Form 8-K and
Exhibit 99.1 hereto relating to the announcement of the results
of operations for the quarter ended December 31, 2016 and all
other matters except for those discussed under Item 8.01 below
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in any such
filings.

The press release referred to in Item 2.02 also provides certain
program updates relating to the Companys AEROSURF phase 2
clinical development program. In addition, the Company reports
that, before any additional financings, the Company anticipates
that it will have sufficient cash to fund its operations through
the planned completion of the AEROSURF phase 2b clinical trial
and announcement of results in mid-year 2017.

Subject to the note relating to the press release contained in
Item 2.02 of this Current Report on Form 8-K, the press release
is attached as Exhibit 99.1 hereto.

Cautionary Note Regarding Forward-looking
Statements:

To the extent that statements in this Current Report on Form 8-K
are not strictly historical, including statements as to business
strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, future
collaboration agreements, the success of the Companys product
development, cash flows, future revenues, the timing of planned
clinical trials or otherwise as to future events, such statements
are forward-looking, and are made to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. The
forward-looking statements contained in this Current Report are
subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
Such risks and others are further described in the Companys
filings with the Securities and Exchange Commission including the
most recent reports on Forms 10-K, 10-Q and 8-K, and any
amendments thereto. Any forward-looking statement made by the
Company in this Current Report on Form 8-K is based only on
information currently available to the Company and speaks only as
of the date on which it is made. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.

About Windtree Therapeutics (NASDAQ:WINT)

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Windtree Therapeutics (NASDAQ:WINT) Recent Trading Information

Windtree Therapeutics (NASDAQ:WINT) closed its last trading session 00.00 at 1.15 with 88,673 shares trading hands.